Nanoparticles of glycol chitosan and its thiolated derivative significantly improved the pulmonary delivery of calcitonin

International Journal of Pharmaceutics

Volumn 397, Issue 1-2, 2010, Pages 92-95

  Makhlof, Abdallah ^a   Werle, Martin ^a   Tozuka, Yuichi ^a   Takeuchi, Hirofumi ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Calcitonin; Glycol chitosan; Nanoparticles; Pulmonary mucoadhesion; Pulmonary peptide delivery; Thiomers

Indexed keywords

CALCITONIN; CHITOSAN; CHITOSAN DERIVATIVE; GLYCOL; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFECT; LUNG PARENCHYMA; LUNG TOXICITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SYNTHESIS;

ABSORPTION; ANIMALS; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DRUG CARRIERS; LUNG; MALE; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; RATS; THIOGLYCOLATES;

EID: 77955983828     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.07.001     Document Type: Article

References (27)

1. Agu R.U., Ugwoke M.I., Armand M., Kinget R., Verbeke N. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2001, 2:198-209.
2. Bernkop-Schnürch A., Weithaler A., Albrecht K., Greimel A. Thiomers: preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system. Int. J. Pharm. 2006, 317:76-81.
3. Clark A., Kuo M., Newman S., Hirst P., Pitacairn G., Pickford M. A comparison of the pulmonary bioavailability of powder and liquid aerosol formulations of salmon calcitonin. Pharm. Res. 2008, 25:1583-1590.
4. Dailey L.A., Schmehl T., Gessler T., Wittmar M., Grimminger F., Seeger W., Kissel T. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J. Control. Release 2003, 86:131-144.
5. Deftos L.J., Nolan J.J., Seely B.L., Clopton P.L., Cote G.J., Whitham C.L., Florek L.J., Christensen T.A., Hill M.R. Intrapulmonary drug delivery of salmon calcitonin. Calcif. Tissue Int. 1997, 61:345-347.
6. Grenha A., Seijo B., Remuñán-López C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 2005, 25:427-437.
7. Hinchcliffe M., Jabbal-Gill I., Smith A. Effect of chitosan on the intranasal absorption of salmon calcitonin in rats. J. Pharm. Pharmacol. 2005, 57:681-687.
8. Kean T., Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv. Drug Deliv. Rev. 2010, 62:3-11.
9. Komada F., Iwakawa S., Yamamoto M., Sakakibara H., Okumura K. Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung. J. Pharm. Sci. 1994, 83:863-867.
10. Lauweryns J.M., Baert J.H. Alveolar clearance and the role of the pulmonary lymphatics. Am. Rev. Respir. Dis. 1977, 115:625-683.
11. Leitner V.M., Walker G.F., Bernkop-Schnürch A. Thiolated polymers: evidence for the formation of disulphide bonds with mucus glycoproteins. Eur. J. Pharm. Biopharm. 2003, 56:207-214.
12. Makhlof A., Werle M., Tozuka Y., Takeuchi H. A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. J. Control. Release 2010, 10.1016/j.jconrel.2010.02.001.
13. 1,7)-eel calcitonin by various protease inhibitors in rats. Pharm Res. 1994, 11:909-913.
14. Patton J.S., Trinchero P., Platz R.M. Bioavailability of pulmonary delivered peptides and proteins: α-interferon, calcitonins and parathyroid hormones. J. Control. Release 1994, 28:79-85.
15. Patton J.S. Mechanisms of macromolecule absorption by the lungs. Adv. Drug. Deliv. Rev. 1996, 19:3-36.
16. Patton J.S. Pulmonary delivery of drugs for bone disorders. Adv. Drug. Deliv. Rev. 2000, 42:239-248.
17. Sakloetsakun D., Hombach J.M., Bernkop-Schnürch A. In situ gelling properties of chitosan-thioglycolic acid conjugate in the presence of oxidizing agents. Biomaterials 2009, 30:6151-6157.
18. Scheuch G., Siekmeier R. Novel approaches to enhance pulmonary delivery of proteins and peptides. J. Physiol. Pharmacol. 2007, 58:615-625.
19. Siekmeier R., Scheuch G. Systemic treatment by inhalation of macromolecules-principles, problems, and examples. J. Physiol. Pharmacol. 2008, 59:53-79.
20. Siekmeier R., Scheuch G. Treatment of systemic diseases by inhalation of biomolecule aerosols. J. Physiol. Pharmacol. 2009, 60:15-26.
21. Trapani A., Sitterberg J., Bakowsky U., Kissel T. The potential of glycol chitosan nanoparticles as carrier for low water soluble drugs. Int. J. Pharm. 2009, 375:97-106.
22. Weissenböck A., Wirth M., Gabor F. WGA-grafted PLGA-nanospheres: preparation and association with Caco-2 single cells. J. Control. Release 2004, 99:383-392.
23. Werle M., Hoffer M. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J. Control. Release 2006, 111:41-46.
24. 1,7]-eel calcitonin from various mucosal administration sites. J. Control. Release 2001, 76:363-374.
25. Yamamoto H., Kuno Y., Sugimoto S., Takeuchi H., Kawashima Y. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J. Control. Release 2005, 102:373-381.
26. Yang W., Peters J.I., Williams R.O. Inhaled nanoparticles - a current review. Int. J. Pharm. 2008, 356:239-247.
27. Youn Y.S., Kwon M.J., Na D.H., Chae S.Y., Lee S., Lee K.C. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. J. Control. Release 2008, 125:68-75.